SHORT MINI-FUTURE - BIOGEN IDEC | Delayed Deutsche Boerse AG 11:15:55 21/05/2024 pm IST | ||
| 21.86 EUR | +2.58% |
|
| Current month | -5.33% | ||
| 1 month | -13.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 21.86 | +2.58% |
| 20/24/20 | 21.31 | -1.07% |
| 17/24/17 | 21.54 | +0.05% |
| 16/24/16 | 21.53 | +2.87% |
| 15/24/15 | 20.93 | -5.08% |
Delayed Quote Deutsche Boerse AG
Last update May 21, 2024 at 11:15 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VQ8H9K |
| ISIN | DE000VQ8H9K1 |
| Date issued | 09/06/2021 |
| Strike | 462.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.81 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.91 € |
|---|---|
| Lowest since issue | 3.82 € |
| Spread | 0.16 € |
| Spread % | 0.73% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
227.7
USD
Average target price
285.9
USD
Spread / Average Target
+25.57%
- Stock Market
- Certificates
- Certificat
